Amphotericin B-loaded poly(lactide)-poly(ethylene glycol)-blend nanoparticles: Characterization and in vitro efficacy and toxicity

Current Nanoscience

Volumn 9, Issue 5, 2013, Pages 594-598

  Rodrigues, Caroline Danziato ^a,b   Casa, Diani Meza ^a   Dalmolin, Luciana Facco ^a   de Camargo, Luciana Erzinger Alves ^a   Khalil, Najeh Maissar ^a   Mainardes, Rubiana Mara ^a  

^a UNIVERSIDADE ESTADUAL DO CENTRO OESTE   (Brazil)

^b Department of Pharmacy ^*  (Brazil)

Author keywords

Amphotericin B; Drug delivery; Hemolysis; In vitro antifungal; Polymeric nanoparticles

Indexed keywords

AMPHOTERICIN B; ANTI-FUNGAL; BIOLOGICAL PARAMETER; ENCAPSULATION EFFICIENCY; ENTRAPMENT EFFICIENCY; HEMOLYSIS; HUMAN ERYTHROCYTES; POLYMERIC NANOPARTICLES;

BLOOD; CANDIDA; DRUG DELIVERY; ENCAPSULATION; POLYETHYLENE GLYCOLS; YEAST;

NANOPARTICLES;

AMPHOTERICIN B; MACROGOL; NANOPARTICLE; POLYLACTIDE;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG EFFICACY; ERYTHROCYTE; HEMOLYSIS; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

EID: 84884249914     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/15734137113099990072     Document Type: Article

References (28)

1. Kullberg, B.J.; Pauw, B.C. Therapy of invasive fungal infections. Neth. J. Med., 1999, 55, 118-127.
2. Torrado, J.J.; Espada, R.; Ballesteros, M.P. Torrado-Santiago, S. Amphotericin B formulations and drug targeting. J. Pharm. Sci., 2008, 97(7), 2405-2425.
3. Sundar, S.; Chakravarty, J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin. Pharmacother., 2013, 14(1), 53-63.
4. Varlam, D.E.; Siddiq, M.M.; Parton, L.A.; Rüssmann, H. Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrob. Agents Chemother., 2001, 45(3), 679-685.
5. Van Etten, E.W.M.; Otte-Lambillion, M.; Van Vianen, W.; ten Kate, M.T.; Bakker-Woudenberg, A.J. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate (AmB-deoxycholate) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J. Antimicrob. Chemother., 1995, 35(4), 509-519.
6. Gold, N.; Stout, H.A.; Pagano, J.F.; Donovick, R. Amphotericin A and B, antifungal antibiotics produced by a streptomycete. In vivo studies. Antibiot. Annu., 1956-1957, 3, 579-586.
7. Serrano, D.R.; Hernández, L.; Fleire. L.; González-Alvarez, I.; Montoya, A.; Ballesteros, M. P.; Dea-Ayuela, M.A.; Miró, G.; Bolás-Fernández, F.; Torrado JJ. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations. Int. J. Pharm., 2013, 447, 38-46.
8. Adler-Moore, J.P.; Proffitt, R.T. Amphotericin B lipid preparations: what are the differences? Clin. Microbiol. Infect., 2008, 14, 25-36.
9. Barratt, G.; Bretagne, S. Optimizing efficacy of Amphotericin B through nanomodification. Int. J. Nanomed., 2007, 2(3), 301-313.
10. Feferbaum, R.; Krebs, V.L.J.; Santos, S.R.C.J.; Diniz, E.M.A.; Galvani, A.L.S.; Vaz, F.A.C. Amphotericin B in Colloidal Dispersion (Amphocil®) serum levels in infants with sistemic candidiasis. Pediatr. Res., 1998, 43(2), 245-245.
11. Wasan, E.K.; Bartlett, K.; Gershkovich, P.; Sivak, O.; Banno, B.; Wong, Z.; Gagnon, J.; Gates, B.; Leon, C.G.; Wasan, K.M. Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int. J. Pharm., 2009, 372(1-2), 76-84.
12. Soppimath, K.S.; Aminabhavi, T. M.; Kulkarni, A.R.; Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release, 2001, 70(1-2), 1-20.
13. Kumari, A.; Yadav, S.K.; Yadav, S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B. Biointerfaces, 2010, 75(1), 1-18.
14. Shao, K.; Huang, R.; Li, J.; Han, L.; Ye, L.; Jiang, C. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J. Control. Release, 2010, 147(1), 118-126.
15. Khalil, N.M.; do Nascimento, T.C.; Casa, D.M.; Dalmolin, L.F.; de Mattos, A.C.; Hoss, I.; Romano, M.A.; Mainardes, R.M. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf. B. Biointerfaces, 2013, 101, 353-360.
16. Owens III, D.E.; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 2006, 307(1), 93-102.
17. Ravikumara, N.R.; Tiyaboonchai, W.; Madhusudhan, B. Fabrication and Characterization of Genistein Encapsulated Poly (D, L) Lactic acid Nanoparticles for Pharmaceutical Application. Curr. Nanosci., 2013, 9(2), 293-302.
18. Van de Ven, H.; Paulussen, C.; Feijens, P.B.; Matheeussen, A.; Rombaut, P.; Kayaert, P.; Van den Mooter, G.; Weyenberg, W.; Cos, P.; Maes, L.; Ludwig, A. PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome. J. Control. Release, 2012, 161(3), 795-803.
19. Italia, J.L.; Kumar, M.N.; Carter, K.C. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis. J. Biomed. Nanotechnol., 2012, 8(4), 695-702.
20. Xu, N.; Gu, J.; Zhu, Y.; Wen, H.; Ren, Q.; Chen, J. Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice. Int. J. Nanomed., 2011, 6, 905-913.
21. Ren, T.; Xu, N.; Cao, C.; Yuan, W.; Yu, X.; Chen, J.; Ren, J. Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles. J. Biomater. Sci. Polym., 2009, 20(10), 1369-1380.
22. Italia, J.L.; Yahya, M.M.; Singh, D.; Ravi Kumar, M.N. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone. Pharm. Res., 2009, 26(6), 1324-1331.
23. Mainardes, R.M.; Khalil, N. M.; Carraro, T. C. M. M.; Rodrigues, C. D.; Casa, D.M.; Dalmolin, L.F. Processo de obtenção de nanopartículas poliméricas contendo o fármaco anfotericina B. Brazil. Patent PI1107204, December 22, 2011.
24. NATIONAL COMMITEE FOR CLINICAL LABORATORY STARDADS. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standards-2 ed. NCCLS document M27-A2. Pennsylvania: NCCLS-2002.
25. Bolard, J.; Legrand, P.; Heitz, F.; Cybulska, B. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its selfassociation in the medium. Biochemistry, 1991, 30(23), 5707-5715.
26. Espada, R.; Vales Pina, S.; Alfonso, C.; Rivas, G.; Ballesteros, M.P.; Torrado, J.J. Effect of aggregation state on the toxicity of different amphotericin B preparations. Int. J. Pharm., 2008, 361(1-2), 64-69.
27. Legrand, P.; Romero, E.A.; Cohen, B.E.; Bolard, J. Effect of aggregation and solvent on the activity of amphotericin B on human erythrocytes. Antimicrob. Agents Chemother., 1992, 36(11), 2518-2522.
28. Adams, M.L.; Kwon, G.S. Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block-poly(Nhexyl-L-aspartamide)-acyl conjugate micelles: effects of acyl chain length. J. Control. Release, 2003, 87(1-3), 23-32.